Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Advanced Bifurcation Systems to Sponsor XIII European Bifurcation Club Meeting | ||
By: Nasdaq / GlobeNewswire - 18 Sep 2017 | Back to overview list |
|
LOS ANGELES, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems ("ABS" or the "Company"), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company will be a sponsor of the XIII European Bifurcation Club (www.bifurc.net) meeting at the Casa Das Artes in Porto, Portugal on Friday, October 13th and Saturday, October 14th, 2017. Dr. Mehran Khorsandi, the Company's co-founder, chairman and chief medical officer will make a presentation entitled "Bifurcations Made Easy" at the conference. "Our platform based technology is unlike anything on the market today. We have put extensive patent protection in place and are working with key institutions and KOL's to advance our program as we move forward to commercialize the technology and pursue regulatory approval," commented CEO Charles Laverty. Advanced Bifurcation Systems, through its novel Mother/Daughter ("MD") platform, has complete coverage for all lesions regardless of branch angle, size, plaque burden or location. This single system addresses both the main and side branch, and is mechanically fail-safe and self-aligning for perfect placement. Dr. Mehran Khorsandi commented, "We have really worked hard to perfect our technology and believe that when we commercialize our product more interventional cardiologists will be comfortable doing complex bifurcations. Our unique technology enables assembly of a bifurcating stent at the carina, regardless of angles, sizes or plaque burden. We expect that our platform, which has been tested in 10 patients to date, will require limited training, greatly reduce procedure times and improve clinical outcomes." About Advanced Birfurcation Systems Advanced Bifurcation Systems ("ABS") is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure. The Company's groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent. For more information, go to www.advancedbifurcation.com .
About EBC 2017
Contact:
Advanced Birfurcation Systems
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Advanced Bifurcation Systems via GlobeNewswire
HUG#2134549
|
||
|
||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |